What is Vidac Pharma?
Vidac Pharma operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of first-in-class oncologic and onco-dermatologic treatments. The company distinguishes itself through a breakthrough technological platform designed to address a fundamental metabolic characteristic shared by cancer cells. By targeting this specific vulnerability, Vidac Pharma aims to establish a new standard of care that can be seamlessly integrated into existing oncology combination regimens. This strategic positioning allows the firm to address significant unmet medical needs, potentially transforming the treatment paradigm for various malignancies and skin-related cancers.
How much funding has Vidac Pharma raised?
Vidac Pharma has raised a total of $9.6M across 2 funding rounds:
Series A
$9M
Other Financing Round
$645K
Series A (2016): $9M with participation from Israel Biotech Fund
Other Financing Round (2024): $645K, investors not publicly disclosed
Key Investors in Vidac Pharma
Israel Biotech Fund
Israel Biotech Fund I LP is a specialized investment firm based in Rehovot, Israel, focusing on high-potential opportunities within the biotechnology and life sciences sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vidac Pharma?
With the recent capital deployment, Vidac Pharma is poised to scale its clinical operations and deepen its research initiatives. The strategic roadmap likely involves the expansion of phase-specific trials to demonstrate the efficacy and safety of its lead candidates in human subjects. Furthermore, the company is expected to leverage this financing to strengthen its intellectual property portfolio and explore potential collaborative opportunities with larger pharmaceutical partners. As the firm moves toward commercialization, the focus will shift from early-stage development to establishing robust clinical data sets that support regulatory filings and long-term market adoption. The successful execution of these milestones will be pivotal in determining the company's ability to disrupt the current oncology market and deliver value to stakeholders.
See full Vidac Pharma company page
